Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indomethacin + ranibizumab
- Development stage
- Phase 4
- Lead developer
- Merck
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravitreal, Ophthalmic
01
Overview
Indomethacin + ranibizumab is a combination therapy used for the treatment of neovascular (wet) age-related macular degeneration (AMD). This combination approach targets both inflammation and vascular endothelial growth factor (VEGF) pathways involved in choroidal neovascularization (CNV). Ranibizumab is administered as an intravitreal injection while indomethacin is given as topical eye drops. Clinical studies have shown that this combination provides superior anatomical and visual outcomes compared to ranibizumab monotherapy, with the additional benefit of potentially reducing the frequency of ranibizumab injections needed.
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on indomethacin + ranibizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indomethacin + ranibizumab.